Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Enanta PharmaceuticalsTrillium TherapeuticsAkero TherapeuticsAvid BioservicesRadius Health
SymbolNASDAQ:ENTANASDAQ:TRILNASDAQ:AKRONASDAQ:CDMONASDAQ:RDUS
Price Information
Current Price$51.10$9.23$27.87$19.01$19.13
52 Week RangeHoldBuyBuyBuyHold
MarketRank™
Overall Score1.41.71.71.71.3
Analysis Score3.13.44.51.53.2
Community Score2.32.92.52.62.7
Dividend Score0.00.00.00.00.0
Ownership Score1.71.71.72.50.0
Earnings & Valuation Score0.00.60.01.90.6
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyHold
Consensus Price Target$65.29$21.83$57.29$17.33$24.60
% Upside from Price Target27.76% upside136.55% upside105.55% upside-8.82% downside28.59% upside
Trade Information
Market Cap$1.03 billion$950.88 million$969.04 million$1.16 billion$897.08 million
Beta0.542.270.582.361.18
Average Volume148,3701,301,207286,390763,455469,267
Sales & Book Value
Annual Revenue$122.47 million$120,000.00N/A$59.70 million$173.32 million
Price / Sales8.427,924.03N/A19.375.18
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$22.70 per share($0.86) per share$4.51 per share$0.74 per share($0.92) per share
Price / Book2.25-10.73N/A25.69-20.79
Profitability
Net Income$-36,170,000.00$-41,620,000.00$-43,760,000.00$-10,470,000.00$-132,990,000.00
EPS($0.89)($1.38)($2.90)($0.27)($2.89)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/A237.63N/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-29.53%N/AN/A0.20%-48.61%
Return on Equity (ROE)-3.75%-70.00%-40.84%0.31%N/A
Return on Assets (ROA)-3.53%-28.84%-38.33%0.13%-56.85%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio18.08%22.44%24.81%1.45%2.25%
Quick Ratio18.08%22.44%24.81%1.22%2.15%
Ownership Information
Institutional Ownership Percentage90.78%67.46%83.49%58.16%N/A
Insider Ownership Percentage10.93%N/A7.09%1.72%2.92%
Miscellaneous
Employees141N/A16222310
Shares Outstanding20.17 million103.02 million34.77 million60.83 million46.89 million
Next Earnings Date5/5/2021 (Estimated)5/21/2021 (Estimated)5/12/2021 (Estimated)6/29/2021 (Estimated)5/6/2021 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableOptionable
SourceHeadline
Radius Health to Announce First Quarter 2021 Financial Results, Host Conference Call and Live ...Radius Health to Announce First Quarter 2021 Financial Results, Host Conference Call and Live ...
apnews.com - April 21 at 12:52 AM
Radius Health to Announce First Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Friday, May 7, 2021Radius Health to Announce First Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Friday, May 7, 2021
finance.yahoo.com - April 20 at 7:52 PM
Radius Health, Inc. (NASDAQ:RDUS) – Analysts’ Revisions Show Sentiment Is ImprovingRadius Health, Inc. (NASDAQ:RDUS) – Analysts’ Revisions Show Sentiment Is Improving
stocksregister.com - April 18 at 9:17 AM
Radius Health, Inc. (NASDAQ:RDUS) Expected to Announce Quarterly Sales of $59.84 MillionRadius Health, Inc. (NASDAQ:RDUS) Expected to Announce Quarterly Sales of $59.84 Million
americanbankingnews.com - April 13 at 6:12 AM
Radius Health, Inc. (NASDAQ:RDUS) Stock Dropped -9.22% Over A Month – Is There Any Hope Of A Gain?Radius Health, Inc. (NASDAQ:RDUS) Stock Dropped -9.22% Over A Month – Is There Any Hope Of A Gain?
marketingsentinel.com - April 12 at 12:45 PM
Arbutus Biopharma (NASDAQ:ABUS) vs. Radius Health (NASDAQ:RDUS) Head-To-Head AnalysisArbutus Biopharma (NASDAQ:ABUS) vs. Radius Health (NASDAQ:RDUS) Head-To-Head Analysis
americanbankingnews.com - April 9 at 4:22 PM
Radius Health (NASDAQ:RDUS) Given Buy Rating at The Goldman Sachs GroupRadius Health (NASDAQ:RDUS) Given Buy Rating at The Goldman Sachs Group
americanbankingnews.com - March 29 at 9:28 AM
The Goldman Sachs Group Reiterates "Buy" Rating for Radius Health (NASDAQ:RDUS)The Goldman Sachs Group Reiterates "Buy" Rating for Radius Health (NASDAQ:RDUS)
marketbeat.com - March 29 at 8:43 AM
Radius Health (RDUS) Up 14.7% Since Last Earnings Report: Can It Continue?Radius Health (RDUS) Up 14.7% Since Last Earnings Report: Can It Continue?
finance.yahoo.com - March 27 at 2:42 PM
Radius Health Provides Update on AbaloparatideRadius Health Provides Update on Abaloparatide
finance.yahoo.com - March 24 at 8:56 AM
Radius Health (RDUS) Soars 14.6%: Is Further Upside Left in the Stock?Radius Health (RDUS) Soars 14.6%: Is Further Upside Left in the Stock?
finance.yahoo.com - March 23 at 12:54 PM
Radius Health, Inc. Announces $175 Million Financing Transaction Nasdaq:RDUSRadius Health, Inc. Announces $175 Million Financing Transaction Nasdaq:RDUS
compsmag.com - March 3 at 8:14 PM
Radius Health, Inc. Announces $175 Million Financing TransactionRadius Health, Inc. Announces $175 Million Financing Transaction
feeds.benzinga.com - March 3 at 4:30 PM
Radius (RDUS) Q4 Loss Wider Than Expected, Revenues BeatRadius' (RDUS) Q4 Loss Wider Than Expected, Revenues Beat
finance.yahoo.com - February 26 at 2:18 PM
Radius Health (RDUS) Q4 2020 Earnings Call TranscriptRadius Health (RDUS) Q4 2020 Earnings Call Transcript
finance.yahoo.com - February 25 at 5:37 PM
Radius Health, Inc.: Fourth Quarter and Full Year ResultsRadius Health, Inc.: Fourth Quarter and Full Year Results
finance.yahoo.com - February 25 at 7:26 AM
Radius Health to Present at 10th Annual SVB Leerink Global Healthcare ConferenceRadius Health to Present at 10th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 17 at 11:41 AM
Radius Health to Announce Fourth Quarter 2020 Financial Results, Host Conference Call and Live ...Radius Health to Announce Fourth Quarter 2020 Financial Results, Host Conference Call and Live ...
apnews.com - February 17 at 6:41 AM
Radius Health to Announce Fourth Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Thursday, February 25, 2021Radius Health to Announce Fourth Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Thursday, February 25, 2021
finance.yahoo.com - February 16 at 12:41 PM
Radius Health, Inc. provides corporate update for abaloparatide Nasdaq: RDUSRadius Health, Inc. provides corporate update for abaloparatide Nasdaq: RDUS
compsmag.com - February 12 at 6:18 PM
Radius Health, Inc. Provides Abaloparatide Business UpdateRadius Health, Inc. Provides Abaloparatide Business Update
finance.yahoo.com - February 12 at 1:17 PM
Radius Health, Inc.s (NASDAQ:RDUS) Shift From Loss To ProfitRadius Health, Inc.'s (NASDAQ:RDUS) Shift From Loss To Profit
finance.yahoo.com - February 9 at 12:36 PM
Whats in Store for Pacific Biosciences (PACB) Q4 Earnings?What's in Store for Pacific Biosciences' (PACB) Q4 Earnings?
finance.yahoo.com - February 9 at 12:36 PM
Aurinia (AUPH) Gets FDA Nod for Kidney Disorder Drug LupkynisAurinia (AUPH) Gets FDA Nod for Kidney Disorder Drug Lupkynis
finance.yahoo.com - January 25 at 12:18 PM
RDUS Feb 2021 25.000 callRDUS Feb 2021 25.000 call
uk.finance.yahoo.com - January 20 at 8:28 PM
RDUS Feb 2021 15.000 putRDUS Feb 2021 15.000 put
uk.finance.yahoo.com - January 20 at 8:28 PM
DateCompanyBrokerageAction
2/9/2021Enanta PharmaceuticalsRoyal Bank of CanadaBoost Price Target
1/29/2021Enanta PharmaceuticalsJPMorgan Chase & Co.Upgrade
11/23/2020Enanta PharmaceuticalsEvercore ISIInitiated Coverage
10/26/2020Enanta PharmaceuticalsRoth CapitalBoost Price Target
9/23/2020Enanta PharmaceuticalsOppenheimerReiterated Rating
8/25/2020Enanta PharmaceuticalsPiper SandlerInitiated Coverage
7/27/2020Enanta PharmaceuticalsJMP SecuritiesUpgrade
3/17/2020Enanta PharmaceuticalsRobert W. BairdUpgrade
9/18/2019Enanta PharmaceuticalsBerenberg BankSet Price Target
5/24/2019Enanta PharmaceuticalsWolfe ResearchInitiated Coverage
8/8/2018Enanta PharmaceuticalsUBS GroupDowngrade
4/20/2021Trillium TherapeuticsBenchmarkInitiated Coverage
3/22/2021Trillium TherapeuticsHC WainwrightReiterated Rating
3/19/2021Trillium TherapeuticsJonestradingReiterated Rating
12/8/2020Trillium TherapeuticsBloom BurtonDowngrade
11/18/2020Trillium TherapeuticsCraig HallumBoost Price Target
1/7/2020Trillium TherapeuticsCowenReiterated Rating
3/29/2021Akero TherapeuticsMorgan StanleyLower Price Target
3/24/2021Akero TherapeuticsCanaccord GenuityLower Price Target
3/23/2021Akero TherapeuticsJefferies Financial GroupReiterated Rating
3/23/2021Akero TherapeuticsChardan CapitalBoost Price Target
3/4/2021Akero TherapeuticsGuggenheimInitiated Coverage
2/1/2021Avid BioservicesKeyCorpBoost Price Target
12/10/2019Avid BioservicesFirst AnalysisUpgrade
12/10/2019Avid BioservicesStephensBoost Price Target
6/28/2019Avid BioservicesJanney Montgomery ScottUpgrade
3/29/2021Radius HealthThe Goldman Sachs GroupReiterated Rating
3/8/2021Radius HealthSVB LeerinkBoost Price Target
1/7/2021Radius HealthCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
1/7/2021Radius HealthSmith Barney CitigroupBoost Price Target
4/23/2020Radius HealthStifel NicolausInitiated Coverage
(Data available from 4/21/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.